ES2963727R1 - Nutraceutical or pharmaceutical composition for use in the treatment and/or prevention of conditions or pathologies characterized by magnesium deficiency - Google Patents

Nutraceutical or pharmaceutical composition for use in the treatment and/or prevention of conditions or pathologies characterized by magnesium deficiency Download PDF

Info

Publication number
ES2963727R1
ES2963727R1 ES202390217A ES202390217A ES2963727R1 ES 2963727 R1 ES2963727 R1 ES 2963727R1 ES 202390217 A ES202390217 A ES 202390217A ES 202390217 A ES202390217 A ES 202390217A ES 2963727 R1 ES2963727 R1 ES 2963727R1
Authority
ES
Spain
Prior art keywords
nutraceutical
prevention
treatment
conditions
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES202390217A
Other languages
Spanish (es)
Other versions
ES2963727A2 (en
Inventor
Maio Umberto Di
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neilos SRL
Original Assignee
Neilos SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neilos SRL filed Critical Neilos SRL
Publication of ES2963727A2 publication Critical patent/ES2963727A2/en
Publication of ES2963727R1 publication Critical patent/ES2963727R1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES202390217A 2021-06-04 2022-06-14 Nutraceutical or pharmaceutical composition for use in the treatment and/or prevention of conditions or pathologies characterized by magnesium deficiency Pending ES2963727R1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102021000014504A IT202100014504A1 (en) 2021-06-04 2021-06-04 “Nutraceutical or pharmaceutical composition for use in the treatment and/or prevention of conditions or pathologies characterized by magnesium deficiency”
PCT/IB2022/055491 WO2022254414A2 (en) 2021-06-04 2022-06-14 Nutraceuticalor pharmaceutical composition for the use in the treatment and/or in the prevention of conditions or diseases characterized by magnesium deficiency

Publications (2)

Publication Number Publication Date
ES2963727A2 ES2963727A2 (en) 2024-04-01
ES2963727R1 true ES2963727R1 (en) 2024-05-07

Family

ID=77801811

Family Applications (1)

Application Number Title Priority Date Filing Date
ES202390217A Pending ES2963727R1 (en) 2021-06-04 2022-06-14 Nutraceutical or pharmaceutical composition for use in the treatment and/or prevention of conditions or pathologies characterized by magnesium deficiency

Country Status (3)

Country Link
ES (1) ES2963727R1 (en)
IT (1) IT202100014504A1 (en)
WO (1) WO2022254414A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019239372A1 (en) * 2018-06-13 2019-12-19 Pharmanutra S.P.A. Composition comprising sucrosomial minerals containing mineral salts for use in conditions of deficiency of such minerals
WO2021099976A1 (en) * 2019-11-19 2021-05-27 Neilos S.r.l. A nutraceutical or pharmaceutical composition comprising iron pyrophosphate for use in the treatment and/or prevention of conditions or diseases characterized by iron deficiency

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1318597B1 (en) * 2000-06-23 2003-08-27 A C R Applied Coating Res S A USE OF A HIGH CONTENT OF EPREGELATINIZED ACETYLATED AMYLOSE.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019239372A1 (en) * 2018-06-13 2019-12-19 Pharmanutra S.P.A. Composition comprising sucrosomial minerals containing mineral salts for use in conditions of deficiency of such minerals
WO2021099976A1 (en) * 2019-11-19 2021-05-27 Neilos S.r.l. A nutraceutical or pharmaceutical composition comprising iron pyrophosphate for use in the treatment and/or prevention of conditions or diseases characterized by iron deficiency

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Ultramag Magnesium" hoja de información del producto. Pureencapsulation.com, 01/03/2018, [en línea][recuperado el 13/03/2024]. Recuperado de Internet (URL:https://www.pureencapsulationspro.com/ultramag-magnesium.html), Documento completo. *
BRILLI, E. ET AL. Magnesium bioavailability after administration of sucrosomial®magnesium:results of an ex-vivo study and comparative, doublé-blinded, cross-over study in healthy subjects. European Review for Medical and Pharmacological Sciences, 01/03/2018, Páginas 1843-1851 [en línea][recuperado el 13/03/2024]. Recuperado de Internet (URL:https://www.europeanreview.org/wp/wp-content/uploads/1843-1851-1.pdf), Documento completo. *
GÓMEZ-RAMÍREZ, S. ET AL. Sucrosomial®Iron: A New Generation Iron for Improving Oral Supplementation". PHARMACEUTICALS, 04/12/2018, Vol. 11, Páginas 97 [en línea][recuperado el 13/03/2024]. Documento complet. *

Also Published As

Publication number Publication date
WO2022254414A3 (en) 2023-11-23
WO2022254414A2 (en) 2022-12-08
IT202100014504A1 (en) 2022-12-04
ES2963727A2 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
CL2012003026A1 (en) Pharmaceutical composition comprising pioglitazone and linagliptin; preparation procedure; Use in the treatment of type 2 diabetes or obesity.
PL3577135T3 (en) A pharmaceutical composition for use in the treatment or prevention of c5-related diseases
ES2525801T8 (en) Compositions and methods for the prevention and treatment of autoimmune diseases
AR110777A1 (en) INDANILAMINOPIRAZINILCICLOPROPANCARBOXÍLICOS ACIDS PHARMACEUTICAL COMPOSITIONS AND ITS USES IN THE TREATMENT OF DISEASES MEDIATED BY GPR40
BR112018005905A2 (en) ? compound, pharmaceutical composition, methods to prevent or treat a disease or condition, organ damage, hepatotoxicity and fatty liver, and, use of a compound?
BRPI0819105A2 (en) composition for the treatment and prevention of eyelid edema
CL2007001945A1 (en) COMPOUNDS DERIVED FROM ALQUILPIRIDAZINA, INHIBITORS OF 11 BETA-HSD1; PROCESS FOR OBTAINING COMPOUNDS; PHARMACEUTICAL COMPOSITION THAT UNDERSTAND THEM; AND USES IN THE TREATMENT OF DIABETES, OBESITY, FOOD INGESTION DISORDER, DISLIPIDE
RS65630B1 (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease
EP4146633A4 (en) Composition for use in the treatment of apol1-associated disease
CL2008003799A1 (en) Pharmaceutical composition comprising raloxifene in immediate release tablet form; Useful for the treatment and / or prevention of osteoporosis.
BRPI0818267A2 (en) New 1,3-dihydro-5-isobenzofuranocarbonitrile derivatives and their pharmaceutical composition for the treatment of premature ejaculation
BR112013014189A2 (en) pharmaceutical composition comprising transcinamaldehyde and its use in the treatment of infections
BRPI0912890A2 (en) pharmaceutical composition for the treatment of premature ejaculation
ES2980790T3 (en) Structurally improved sulfur-containing fatty acids for use in the treatment of non-alcoholic steatohepatitis
CL2012003006A1 (en) Compounds derived from unsaturated steroid lactones in position 7 (8) and their pharmaceutically acceptable salts and stereoisomers; pharmaceutical composition that includes them; and its use for the treatment of cancer.
CL2015000333A1 (en) Bir2 and / or bir3 inhibitor azaheterocycles; pharmaceutical composition; and use in the treatment of cancer.
CL2011001777A1 (en) Pharmaceutical composition containing aleglitazar; process to prepare said pharmaceutical composition; and its use for the treatment or prophylaxis of type II diabetes or cardiovascular diseases.
CL2017000884A1 (en) Pharmaceutical composition for use in the treatment or prevention of vitamin and mineral deficiencies in patients who have undergone gastric bypass surgery
IT201900021564A1 (en) Nutraceutical or pharmaceutical composition including iron pyrophosphate for use in the treatment and / or prevention of conditions or diseases characterized by iron deficiency
CL2013000542A1 (en) Compounds derived from substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides, modulators kcnq2 / 3; pharmaceutical composition; and its use for the treatment or prophylaxis of pain, preferably acute pain, chronic pain, neuropathic pain, visceral pain. epilepsy, migraine, among others.
ES2981079T3 (en) Compounds and their use for the treatment of alpha1-antitrypsin deficiency
ES2963727R1 (en) Nutraceutical or pharmaceutical composition for use in the treatment and/or prevention of conditions or pathologies characterized by magnesium deficiency
CO2019007671A2 (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of Alzheimer's disease
ES2660372T8 (en) Substances and procedures for use in the prevention and / or treatment of Huntington's disease
CO2019002853A2 (en) Tesofensine compositions

Legal Events

Date Code Title Description
BA2A Patent application published

Ref document number: 2963727

Country of ref document: ES

Kind code of ref document: A2

Effective date: 20240401

EC2A Search report published

Ref document number: 2963727

Country of ref document: ES

Kind code of ref document: R1

Effective date: 20240426